Search bioRxiv⌕ Search

bioRxiv · 10.1101/2025.11.21.689652

Glutamine alters the response to stress in mice with diet-induced obesity in a sex-dependent manner.

Abstract

RationalePatients with class III obesity often suffer from irritable bowel syndrome (IBS) while obesity and IBS share common pathophysiological mechanisms such as altered intestinal barrier function and gut microbiota dysbiosis. Oral glutamine (Gln) supplementation previously showed beneficial effects on gut barrier function in a sex-dependent manner and reduced abdominal pain in IBS patients. Thus, we assessed the sex-dependent response to an oral Gln supplementation in mice with diet-induced obesity and subjected to a chronic restraint stress to mimic IBS. MethodsMale (M) and female (F) C57BL/6 mice received a high fat diet (HFD; 60% kcal from fat) during 14 weeks (W14) and were subjected or not to a restraint stress (S) for the 4 last days. From W12, mice received or not Gln in drinking water (2g/kg/day; n=12/group). Plasma corticosterone, body composition, glucose tolerance (OGTT), intestinal permeability, inflammatory markers in colonic and white adipose tissues, cecal microbiota and short-chain fatty acid (SCFA) composition have been assessed. Within each sex, groups were compared by Kruskal-Wallis test or a 1-way ANOVA test. ResultsIn M-HFD mice, chronic restraint stress was associated with a better glucose tolerance (-15,46% AUC) and a reduced fasting glycemia that was not observed in F-HFD mice. Gln partially prevented body weight loss, reduced plasma resistin, plasma corticosterone and colonic permeability in female stressed obese mice. In male stressed obese mice, Gln limited lean mass loss, reduced colonic permeability and Ccl2 mRNA level in the subcutaneous adipose tissue. Chronic restraint stress and Gln modified cecal microbiota in both sexes but cecal SCFA composition only in male mice. In particular, stress induced an increased abundance of Pseudomonadota in male mice that was partially restored after Gln supplementation. In addition, cecal total SCFA were reduced in Gln-supplemented stressed HFD male mice compared to unstressed HFD mice. In female HFD mice, stress associated to Gln supplementation increased the abundance of Thermodesulfobacteriota and reduced colonic expression of Cxcr3 mRNA. ConclusionsChronic restraint stress has beneficial effects on glycemia control in male HFD mice without additive effects of Gln supplementation. By contrast, Gln reduces stress-induced corticosterone level and body weight loss only in females. These data, as well as the differential impact of Gln on intestinal permeability and gut microbiota according to the sex, deserves further investigations to decipher the underlying mechanisms.

Explore related subjects

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

Lefebvre, C., Tiffay, A., Breemeersch, C.-E., Dreux, V., Bole-Feysot, C., Guerin, C., Breton, J., Langlois, L., Maximin, E., Monnoye, M., Dechelotte, P., Douard, V., Goichon, A., Coeffier, M.. 2025-11-21. Glutamine alters the response to stress in mice with diet-induced obesity in a sex-dependent manner.. https://doi.org/10.1101/2025.11.21.689652

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related preprints

Negative association between nodular stromal fibrosis and large lipid droplets in human choroid plexus epithelial cells

Fibrosis is an age-related change within the human choroid plexus that is likely to affect its function negatively. We systematically analyzed nodular stromal fibrosis present in postmortem tissue from a large repository encompassing the human lifespan. Following manual annotation of sampled images from 81 specimens of choroid plexus from the atrium of the lateral ventricle, a deep learning model was trained to assess stages of fibrosis (dense, hyalinized, and mineralized) occurring in papillae across whole slide images of hematoxylin and eosin-stained sections from 204 cases. The percentage of affected papillae and the relative area of fibrosis at all three stages of severity increased with age. Affected papillae were significantly clustered across the choroid plexus, with areas of high and low fibrotic density. Choroid plexus epithelial cells (CPECs) associated with fibrotic papillae were less likely to contain large lipid droplets than were non-fibrotic papillae, as assessed by another deep learning model. Across papillae within a case, the area of each stage of fibrosis was negatively correlated with the prevalence of CPECs containing large lipid droplets. Finally, individuals displaying more nodular fibrosis had significantly fewer CPECs containing large lipid droplets. Thus, age-related nodular stromal fibrosis may negatively impact lipid storage and homeostasis for the choroid plexus and brain.

pathology↗

SilencioM: silencing connected interfering oligonucleotides against MAPT as a potential disease modifying therapeutic for tauopathies

Tauopathies are a diverse group of neurodegenerative diseases whose pathogenesis involves brain accumulation of misfolded, pathological tau (Microtubule Associated Protein Tau, MAPT). More than twenty tauopathies have been identified thus far that collectively impact millions of people worldwide, of which the most common is Alzheimer's disease (AD). Despite substantial efforts to develop drugs for tauopathies, no effective treatments currently exist, highlighting the urgent need for therapeutics to combat these prevalent and ruinous neurodegenerative diseases. Strategies that target tau are likely to have the greatest impact since tau is the proximal cause of their pathogenesis. Small interfering RNAs (siRNAs) have emerged as a powerful class of precision therapeutics that silence disease-causing genes through RNA interference with favorable safety profiles. Delivery challenges are rapidly being addressed, and siRNA-based approaches are poised to transform the therapeutic landscape of neurological diseases. In this study, we describe SilencioM (Silencing connected interfering oligonucleotides against MAPT) and show its efficacy in markedly reducing tau pathology after a single intracerebroventricular injection in PS19 mice, a mouse model of severe tauopathy. SilencioM targets human, primate, rat and mouse ortholog genes; thus, the same compound can proceed from efficacy studies to Investigational New Drug Application (IND)-enabling studies. SilencioM is simple to manufacture and is administered without encapsulation in lipid nanoparticles and without requirements for lipophilic conjugation, making it a promising candidate for further development as a novel therapeutic for tauopathies, including AD.

pathology↗

SilencioMA: A single compound that targets both MAPT and APP as a potential disease modifying therapeutic for Alzheimer's Disease

Alzheimer's Disease (AD) is the most common age-related neurodegenerative disease and the leading cause of dementia worldwide. AD pathogenesis involves aggregation of amyloid-beta (A{beta}), produced from amyloidogenic proteolytic processing of Amyloid Precursor Protein (APP), and accumulation of misfolded, pathological tau (Microtubule Associated Protein Tau, MAPT). Current efforts focus on developing disease modifying therapeutics (DMTs) against single targets: A{beta} or tau. However, DMTs that concurrently target both tau and A{beta} are likely to have the greatest impact since they target both culprits of AD pathogenesis. Here we describe the development of SilencioMA, a single compound that targets both MAPT and APP messenger RNAs (mRNAs) based on silencing connected interfering oligonucleotides against MAPT and APP. Cerebrospinal fluid (CSF) administration of SilencioMA reduces A{beta} and tau and pathology after a single intracerebroventricular injection in 5XFAD/PS19 mice, an animal model of severe amyloidosis and tauopathy. SilencioMA does not rely on lipid nanoparticles or lipophilic conjugates for CSF administration. At the same time its modular design permits conjugation of ligands that facilitate transcytosis through the blood brain barrier, allowing systemic administration. Our findings provide proof-of-concept for a strategy that targets the dual A{beta} and tau pathologies of AD, and establishes a compelling foundation for further development of SilencioMA as a next-generation DMT for AD.

pathology↗